Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Whereas the treatment difference was nominally significant in IFNGS-high patients (treatment difference: 18.2% (95% CI 10.5 to 25.8); nominal p<0.001), it did not reach nominal significance in IFNGS-low patients (treatment difference: 9.3% (95% CI –8.0 to 26.5) nominal p = 0.292), although the sample size of the IFNGS-low group was small (17.4% of the overall study population) ( figure 1 ; table 1 ).

also in 7,732 other papers